Who is eligible for clinical trial NCT04739072?

Participants must meet protocol criteria for Colorectal Adenocarcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04739072 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-27

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study (NCT04739072)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: M.D. Anderson Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (3 items).

Location: Banner - MD Anderson Cancer Center — Gilbert, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age ≥ 18 years.
Histological/cytological confirmation of colorectal adenocarcinoma.
Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
Ability to understand and the willingness to sign a written informed consent document.
Willing to pursue standard of care surveillance post completion of curative therapies.
Willing to provide blood samples for correlative research.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (10 Sites)

Banner - MD Anderson Cancer Center — Gilbert, Arizona
Baptist- MD Anderson Cancer Center — Jacksonville, Florida
The Queen's Medical Center — Honolulu, Hawaii
St. Luke's Cancer Institute — Boise, Idaho
Cooper Hospital UNIV MED CTR. — Camden, New Jersey
UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
Houston Methodist Cancer Center — Houston, Texas
M D Anderson Cancer Center — Houston, Texas
UT Health San Antonio MD Anderson Cancer Center — San Antonio, Texas
Baylor Scott & White Research Institute — Temple, Texas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗